Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cisplatin in Mesothelioma, Malignant: NCT03319537 Clinical Landscape Report 2026
16 October 2026
NCT03319537 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Galgt2 gene therapy (Nationwide Childrens Hospital) in Muscular Dystrophy, Duchenne: NCT03333590 Clinical Landscape Report 2026
16 October 2026
NCT03333590 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avelumab in Mesothelioma, Malignant: NCT03399552 Clinical Landscape Report 2026
16 October 2026
NCT03399552 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ifetroban in Cardiomyopathy, Dilated: NCT03340675 Clinical Landscape Report 2026
16 October 2026
NCT03340675 clinical landscape for Cardiomyopathy, Dilated: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tamoxifen Citrate in Muscular Dystrophy, Duchenne: NCT03354039 Clinical Landscape Report 2026
16 October 2026
NCT03354039 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Mesothelioma, Malignant: NCT03393858 Clinical Landscape Report 2026
16 October 2026
NCT03393858 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGT-001 in Muscular Dystrophy, Duchenne: NCT03368742 Clinical Landscape Report 2026
16 October 2026
NCT03368742 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vesleteplirsen in Muscular Dystrophy, Duchenne: NCT03375255 Clinical Landscape Report 2026
16 October 2026
NCT03375255 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT03375164 Clinical Landscape Report 2026
16 October 2026
NCT03375164 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fordadistrogene movaparvovec in Muscular Dystrophy, Duchenne: NCT03362502 Clinical Landscape Report 2026
16 October 2026
NCT03362502 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cosyntropin in Muscular Dystrophy, Duchenne: NCT03400852 Clinical Landscape Report 2026
16 October 2026
NCT03400852 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deramiocel in Muscular Dystrophy, Duchenne: NCT03406780 Clinical Landscape Report 2026
16 October 2026
NCT03406780 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.